Sequenom Sells Multiple Mass Array Systems in China

Sequenom, Inc., (San Diego, CA, USA) a provider of fine mapping genotyping, methylation, and gene expression-analysis solutions, announced the sales of multiple MassArray systems in China. Sequenom's customers include the Beijing Genomics Institute (BGI; Beijing, China), Asia's largest genetic sequencing center, and CapitalBio (Beijing, China), a life-science service company with capacities for whole genome association studies.

The MassArray system is a high-performance DNA analysis platform that efficiently and precisely measures the amount of genetic target material and variations therein. The system is able to deliver reliable and specific data from complex biologic samples and from genetic target material that is only available in trace amounts.

Dr. Wang Wei, BGI director of Viral Genotyping, said, "We chose Sequenom's MassArray technology because it features a unique combination of throughput, accuracy, sensitivity, reproducibility, and cost efficiency. It is particularly suitable for the high-volume viral genotyping project and other population screening projects we plan to undertake in the near future.”

Sequenom's president and CEO Harry Stylli, Ph.D. said, "We view the Chinese market as a very attractive opportunity to expand our genetic analysis business. We believe that sales to the distinguished research institute BGI and a leading service provider CapitalBio demonstrate the effectiveness of our activities to penetrate the growing Chinese market.”

Sequenom develops genomic and genetic analysis systems for molecular diagnostic markets and research. The company aims to develop products that translate genomic science into superior solutions for biomedical research, agricultural applications, molecular medicine, non-invasive prenatal diagnostics, and clinical utility.


Related Links:
Sequenom
Beijing Genomics Institute
CapitalBio